2018年11月7日 · We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular …

2015年4月16日 · Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin–kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) …

2024年2月25日 · Three pharmaceutical products in the United States reduce PCSK9 activity: alirocumab, evolocumab, and inclisiran. Alirocumab and evolocumab are fully humanized …

Alirocumab was the first agent in the new class of PCSK9 inhibitors to be approved for clinical use. It is indicated as an adjunct to diet and maximally tolerated statin therapy in adults with …

Alirocumab and evolocumab are fully humanized monoclonal antibodies that bind free plasma PCSK9, promoting degradation of this enzyme [8-11]. As a result, less free PCSK9 is available …

This study compared the strength of the evidence base for each of the PCSK9 inhibitors alirocumab and evolocumab. The evidence base for alirocumab is stronger than evolocumab …

2016年12月16日 · Our study, which demonstrates that inhibition of PCSK9 with alirocumab increases the removal of LDL from the circulation by the LDLR, increases confidence that …

Alirocumab is a safe and effective adjunct to diet and maximally tolerated statin therapy in patients who require additional lowering of LDL-C levels. By inhibiting the action of PCSK9 in the liver, …

Alirocumab (also known as SAR236553/REGN727) is a monoclonal antibody that binds circulating PCSK9 and blocks its interactions with surface LDLR. Alirocumab clinical trials with …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates LDL receptor expression and circulating levels of LDL-C. Antibodies to PCSK9 can produce substantial and sustained …